Depo-Provera Cases in 2026: Intake Strategy for Plaintiff Law Firms

Why the Depo-Provera Lawsuit Brain Tumor Meningioma 2026 Window Is Open Now

Depo-Provera is an active mass tort in 2026 involving claims of intracranial meningioma linked to long-term use of the contraceptive injection, with MDL 3140 currently in early-stage discovery. A 2023 British Medical Journal study documented a 5.6-fold increased risk of brain tumor development among long-term users. For plaintiff firms, this represents a critical intake window: the claimant pool remains largely untapped, causation science is recent, and settlement valuations have not yet compressed.

At Mass Tort Ad Agency, we’ve managed over $250 million in Facebook ad spend across 600+ plaintiff law firms handling 100+ mass torts. We’ve seen the pattern repeatedly: the firms that move first in early-stage MDLs lock in premium CPLs, build strong client relationships, and establish market position before the landscape shifts. The Depo-Provera meningioma litigation is wide open right now. Women across the United States who relied on this contraceptive for years—particularly those in Medicaid and Title X family planning programs—are still discovering their diagnoses and have no idea a lawsuit option exists.

The Legal Landscape: Depo-Provera Lawsuit Brain Tumor Meningioma 2026 Is Rapidly Growing

MDL 3140 was centralized in the Northern District of Florida in early 2024 before Judge M. Casey Rodgers. As of mid-2024, more than 3,500 plaintiffs have joined the consolidation, and the filing trend is accelerating. This is one of the fastest-growing mass torts currently in motion—comparable to the early phases of talc litigation or transvaginal mesh when smart firms moved first and built massive portfolios.

The causation anchor is rock-solid. The Traore study examined a French cohort of nearly 1 million women and found that Depo-Provera use—particularly continuous use for 5 or more years—was associated with a statistically significant 5.6-fold increased risk of intracranial meningioma. Medroxyprogesterone acetate, the active ingredient in Depo-Provera, is known to stimulate meningioma growth through progesterone receptor pathways. The mechanism is understood; the epidemiological link is documented; and Pfizer’s knowledge of the risk is a legitimate question for discovery.

No bellwether trials have been selected yet. Pfizer has made no settlement overtures. The MDL is in active discovery phase, with bellwether selection estimated for 2026 and first trials expected in 2027. This timing is critical: we’re operating in the sweet spot where the science is new enough to attract cases at strong CPLs, but the legal landscape is mature enough that judges, defendants, and opposing counsel have a clear roadmap. Early campaigns now will yield the largest cohorts before trial outcomes—favorable or otherwise—begin to affect pricing and demand.

Who Qualifies: The Criteria for a Depo-Provera Meningioma Claim

The eligibility criteria are straightforward and broad—which is exactly why this tort has legs. Any woman who meets these basic qualifications has a viable claim:

• Used Depo-Provera injections (medroxyprogesterone acetate) for 1 year or longer. Cases are stronger with 5+ years of continuous use, but the threshold is just 12 months.
• Diagnosed with intracranial meningioma of any grade. The tumor can be benign or atypical; what matters is the meningioma diagnosis itself.
• Meningioma confirmed by imaging (MRI or CT scan) or surgical pathology. This is a factual bar, not a medical opinion—either the diagnosis is documented or it isn’t.
• Meningioma required monitoring, medication, or surgical intervention. Incidental findings and asymptomatic tumors may qualify, but active treatment strengthens the case.
• Last Depo-Provera injection occurred within the applicable statute of limitations window (varies by state, typically 2-4 years from diagnosis or discovery of the link).

The geographic footprint is nationwide. Depo-Provera was marketed and distributed across all 50 states. Medicaid coverage and Title X funding made it particularly popular in lower-income and rural communities—demographics that are often underserved by mass tort advertising. This is a genuine geographic opportunity, not a regional tort limited to specific districts.

The Advertising Opportunity: Depo-Provera Lawsuit Brain Tumor Meningioma 2026 Claimant Pool Size and CPL Dynamics

Estimating the total addressable claimant pool requires understanding Depo-Provera’s historical usage patterns. The contraceptive has been on the market since the 1990s and has been widely used—particularly in underserved populations where cost and convenience matter. Conservative estimates suggest millions of women have used Depo-Provera at some point. The meningioma incidence rate in the general population is roughly 3-4 per 100,000 women per year. Among long-term Depo-Provera users, the Traore study suggests this risk increases 5.6x.

That math translates to a very large addressable market. If even 10% of long-term Depo-Provera users develop meningioma, and a fraction of those become litigants, you’re looking at tens of thousands of potential claimants nationally. Most of these women have never heard of the Traore study. They don’t know Pfizer faces liability. They think their tumor was just bad luck.

Current CPLs for Depo-Provera meningioma cases are running $3,500 to $6,500 per qualified lead, depending on case strength and geographic focus. These are pre-bellwether prices—meaning they reflect the current cost of qualified case acquisition before any jury verdicts or settlements come in to anchor market expectations. Once bellweller trials occur in 2027, these CPLs will likely shift (either up or down, depending on outcomes). If you acquire cases now at $4,500 CPL and bellwethers return $2M+ per plaintiff, your ROI will be extraordinary. If verdicts disappoint, your costs will spike. The argument for moving now is self-evident.

Our Facebook advertising approach targets women aged 35-65 (peak demographic for meningioma diagnosis after historical Depo-Provera use) in all markets, with concentrated spend in states with high Medicaid penetration and family planning program usage. We segment by healthcare and contraceptive interest, target meningioma-adjacent symptom searches (headaches, vision changes, neurological symptoms), and use creative that connects the dots between Depo-Provera use and meningioma risk. Retargeting is aggressive because many women won’t convert on first exposure—they need to see the Traore study, understand the connection, and overcome the psychological barrier of believing their own tumor wasn’t just random bad luck.

What MTAA Delivers: Campaign Management End-to-End

We’ve built MTAA’s reputation on transparent, outcome-focused mass tort advertising. Our cost-plus pricing model (ad spend plus 15% management fee) means we have zero incentive to burn your budget on inefficient placements or vanity metrics. We measure every campaign against cost per qualified lead, not clicks or impressions.

For Depo-Provera meningioma cases specifically, here’s what we handle:

• Campaign strategy and targeting: We identify the highest-intent female audiences using Depo-Provera exposure signals, meningioma diagnosis signals, and neurological symptom history. We build custom audiences from your existing client base (lookalike modeling) and layer in third-party medical and demographic data to expand reach without diluting quality.
• Creative development: We produce educational video, static carousel ads, and dynamic lead-gen templates that explain the Traore study, the FDA’s growing scrutiny of Depo-Provera, the litigation landscape, and what qualification looks like. We A/B test messaging (scientific credibility vs. personal story vs. settlement potential) to maximize engagement and qualification rates.
• Landing page and intake optimization: We build or integrate with your intake forms to collect the specific data points you need: Depo-Provera use dates and duration, meningioma diagnosis date and imaging results, current symptoms, medical treatment history. We optimize for mobile (80% of our mass tort traffic is mobile) and use progressive disclosure to avoid form abandonment.
• Real-time management and optimization: We monitor CPL daily, adjust bids and targeting in real time, pause underperforming audiences, and scale winners. We provide weekly dashboards showing spend, leads, CPL, and lead quality metrics. We’re transparent about what’s working and what’s not.
• Compliance and landing page hosting: We ensure all creative and landing pages comply with applicable advertising rules, state bar guidelines, and Facebook policies. We own the landing page infrastructure so your firm maintains control of lead data and client relationships.

Over the past 15 years managing $250M+ in Facebook ad spend for 600+ law firms across 100+ mass torts, we’ve learned that scale and speed matter. The firms that dominate early-stage MDLs are the ones that move decisively in the first 6-12 months, when CPLs are reasonable and the claimant pool is hungry for information. Waiting for bellwether trials to come in is a strategy for becoming a second-mover in a second-mover market.

Why Now: The Case for Building Your Depo-Provera Docket in 2024-2026

Three factors converge to make this the ideal time to launch a Depo-Provera lawsuit brain tumor meningioma 2026 campaign:

First, the science is new and credible. The Traore study is less than two years old. It’s peer-reviewed, published in a top-tier journal, and finding real traction among plaintiff’s bar networks. Pfizer hasn’t successfully challenged the methodology or the 5.6x risk finding. This causation anchor is clean and strong.

Second, the claimant pool is untapped. Most women with Depo-Provera-associated meningiomas don’t know the link exists. They’ve had their surgeries, their imaging, their neurological treatment—and they’ve moved on. Your advertising is introducing them to a litigation option they didn’t know they had. This is low-hanging fruit in terms of case acquisition efficiency.

Third, MDL economics are favorable now. No bellwether verdicts means no settlement range, no published damages benchmarks, and no anchor to pull CPLs up or down. You’re operating in a window where you can qualify cases at pre-verdict CPLs. Once Judge Rodgers convenes the first bellwethers in 2026-2027, case values will crystallize, CPLs will shift, and demand will respond. Moving now lets you build scale before that repricing occurs.

The Closing Argument: Depo-Provera Lawsuit Brain Tumor Meningioma 2026 Is Your Campaign to Win

Mass Tort Ad Agency has spent 15+ years helping plaintiff firms identify and capture early-stage tort opportunities. The Depo-Provera lawsuit brain tumor meningioma 2026 litigation checks every box: strong causation science, broad eligibility criteria, massive addressable market, favorable CPL dynamics, and a timeline that rewards speed. This isn’t a speculative play; it’s a documented epidemiological link backed by peer-reviewed evidence and a rapidly growing MDL.

If you’re managing a plaintiff practice and you’re not thinking about Depo-Provera meningioma cases yet, your competitors are. The window for efficient case acquisition is open now—between mid-2024 and the 2026 bellwether phase. Once trial outcomes come in, the market will reprice, CPLs will shift, and early-mover advantage will evaporate.

Let’s talk about building your Depo-Provera docket. MTAA can have a campaign live and generating qualified leads within 2-3 weeks. We’ll manage the entire Facebook advertising operation on a transparent cost-plus model: you pay the ad spend (to Meta), you pay our 15% management fee, and we handle strategy, creative, targeting, optimization, compliance, and reporting. No surprises. No vanity metrics. Just qualified Depo-Provera meningioma cases acquired at the CPL rate that makes financial sense for your firm.